Acumen Pharmaceuticals, Inc. (ABOS): Price and Financial Metrics
GET POWR RATINGS... FREE!
ABOS Stock Price Chart Interactive Chart >
ABOS Price/Volume Stats
| Current price | $3.56 | 52-week high | $26.98 |
| Prev. close | $3.48 | 52-week low | $3.02 |
| Day low | $3.38 | Volume | 77,500 |
| Day high | $3.61 | Avg. volume | 233,651 |
| 50-day MA | $4.03 | Dividend yield | N/A |
| 200-day MA | $8.74 | Market Cap | 144.18M |
Acumen Pharmaceuticals, Inc. (ABOS) Company Bio
Acumen Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in the development of therapeutics for the treatment of Alzheimer's and other neurodegenerative diseases. The company focuses on advancing a targeted immunotherapy drug candidate ACU193, which is in Phase I clinical-stage to target soluble amyloid-beta oligomers. Acumen Pharmaceuticals, Inc. was incorporated in 1996 and is based in Charlottesville, Virginia.
Latest ABOS News From Around the Web
Below are the latest news stories about Acumen Pharmaceuticals Inc that investors may wish to consider to help them evaluate ABOS as an investment opportunity.
Bullish Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insiders filled their treasuries with US$5.7m worth of stock over last yearMultiple insiders secured a larger position in Acumen Pharmaceuticals, Inc. ( NASDAQ:ABOS ) shares over the last 12... |
Comparing Acumen Pharmaceuticals (NASDAQ:ABOS) and Adverum Biotechnologies (NASDAQ:ADVM)Adverum Biotechnologies (NASDAQ:ADVM) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their profitability, analyst recommendations, dividends, risk, valuation, earnings and institutional ownership. Valuation and Earnings This table compares Adverum Biotechnologies and Acumen Pharmaceuticals revenue, earnings per share [] |
Acumen Pharmaceuticals (NASDAQ:ABOS) Lowered to Sell at Zacks Investment ResearchZacks Investment Research cut shares of Acumen Pharmaceuticals (NASDAQ:ABOS) from a hold rating to a sell rating in a research note released on Tuesday morning, Zacks.com reports. According to Zacks, Acumen Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company. It involved in developing a novel disease for Alzheimer. The companys product pipeline consist ACU193. Acumen Pharmaceuticals [] |
Ocugen (NASDAQ:OCGN) versus Acumen Pharmaceuticals (NASDAQ:ABOS) Critical ContrastOcugen (NASDAQ:OCGN) and Acumen Pharmaceuticals (NASDAQ:ABOS) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, dividends, profitability, risk, institutional ownership and earnings. Analyst Ratings This is a summary of current recommendations and price targets for Ocugen and Acumen […] |
15 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA CapitalIn this piece, we will take a look at the top 15 pharmaceutical stocks to buy according to Peter Kolchinsky’s RA Capital. If you want to skip our introduction and take a look at the top five stocks in this list, head on over to 5 Pharmaceutical Stocks to Buy According to Peter Kolchinsky’s RA […] |
ABOS Price Returns
| 1-mo | -7.77% |
| 3-mo | -39.25% |
| 6-mo | -54.94% |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -47.34% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
| 2017 | N/A |
Loading social stream, please wait...